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Original Article
Comparison between Tramadol and Pethidine in Patient Controlled Intravenous
Analgesia
Faisal Shamim1, Muhammad Qamarul Hoda2, Khalid Samad3, Salman Sabir4
Departments of Anaesthesia1-3 and Community Health Sciences4, Aga Khan University, Karachi.

Abstract
Objective: To compare the efficacy and side effects related to Tramadol with Pethidine in patient controlled intravenous analgesia (PCIA) after total abdominal hysterectomies.
Methods: A total of 60 patients were randomized to receive either Tramadol or Pethidine by PCIA (30 in each
group) after total abdominal hysterectomy. Pain assessments were recorded one hour after starting the PCIA and
then at 6, 12, and 24 hours by using visual analogue scale (VAS). Nausea vomiting score and sedation score
were also recorded. Good attempts, total attempts and total drug consumption was noted from PCIA pump at the
end of the study period.
Results: The analgesia achieved in Tramadol group was comparable to Pethidine. The incidence of nausea and
vomiting was similar in both groups. Tramadol causes significantly less sedation than Pethidine (p < 0.05). Mean
drug consumption, total attempts and good attempts were also significantly less in Tramadol group than
Pethidine group (p < 0.05).
Conclusion: Tramadol produces equivalent analgesia and less sedation and can be used as an alternative to
Pethidine in Patient Controlled Intravenous Analgesia for postoperative pain relief after Total Abdominal
Hysterectomy (TAH) (JPMA 56:433;2006).

Introduction
Despite constantly increasing understanding of pain
mechanisms and improved technology in pain therapy, the
provision of adequate postoperative pain relief is still a
challenge. Adequate pain control improves recovery from
surgery by reducing stress and by avoiding pulmonary complications.1
Patient Controlled Intravenous Analgesia (PCIA)
has become an established technique for the treatment of
postoperative pain.2 It has been shown to offer a number of
advantages including good analgesia, avoidance of fluctuations in analgesia level, lower total analgesic dosage, and
improved patient satisfaction.3 The typical side-effects of
opioids, such as nausea and vomiting, sedation, respiratory
depression, and pruritus may sometimes hamper the successful application of PCIA.4
Tramadol is a centrally acting analgesic with a low
affinity for µ-opioid receptors. In addition, it also inhibits
the neuronal reuptake of noradrenaline and 5-hydroxytryptamine (5-HT) and it facilitates 5-HT release. The advantages of Tramadol over traditional opioids are minimal
potential for tolerance, addiction and respiratory depression.5 Tramadol has lack of gastrointestinal side-effects and
its reduced incidence of constipation (compared with other
opioids) gives it great value for prolonged use.6
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Morphine and Pethidine are the most commonly
used dugs in PCIA. Unfortunately, both these drugs are not
freely available in Pakistan. This double blind, randomized
controlled trial was designed to compare efficacy and side
effects between Tramadol and Pethidine in PCIA after total
abdominal hysterectomies.

Patients and Methods
The study was performed at a University Hospital
after approval from Ethics Review Committee and after
informed consent from the patients. The study included 60
ASA I-II patients (30 in each group) with ages of 40 to 60
years undergoing total abdominal hysterectomy who were
randomly assigned to one of the group: group A (Tramadol)
and group B (Pethidine). The exclusion criteria were contraindications to opioid drugs, inability to understand the
instructions because of language barrier, history of substance abuse, severe respiratory disease and patients on
Monoamine Oxidase Inhibitors (MAO).
All patients were premedicated with midazolam 7.5
mg orally 45-60 minutes prior to induction of anaesthesia
with Pethidine 1mg/kg. Thiopental 5 mg/kg and atracurium
0.5 mg/kg was administered to facilitate tracheal intubation.
Anaesthesia was maintained with isoflurane 1-1.5% in a
mixture of 60% nitrous oxide and 40% oxygen. Routine
monitoring done with electrocardiogram, NIBP (Non
Invasive Blood Pressure), Pulse oximetry, Capnography
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(ETCO2), FIO2 and inhalational anaesthetic concentration were used in every patient. At the end of surgery,
residual neuromuscular blockade was antagonized by 2.5
mg neostigmine and 1 mg atropine. All patients were given
metoclopramide 10mg intravenous 20 minutes before the
end of surgery.
In the recovery room, PCIA pump (Graseby 3300)
was connected to the patient through a separate intravenous
line. The PCIA drug solution contained either Tramadol
(group A) 10 mg/ml or Pethidine (group B) 10 mg/ml
(labeled as PCIA drug). The PCIA pump was programmed
to deliver a continuous (basal) infusion of study drug
10mg/hr, bolus dose 5 mg (0.5 ml) with a lockout period of
10 minutes in each group. A second intravenous line was
used for maintaining fluids.
Pain assessment was done and recorded by primary
investigator 1 hour after the start of PCIA and then at 6, 12,
and 24 hours by using visual analogue scale (0-10). Nausea
vomiting score7 assessed and recorded by using a scale of 03: (0=no nausea vomiting; 1=mild, no treatment needed;
2=moderate, treatment needed and 3=severe; unresponsive
to simple antiemetics). Sedation score7 was assessed by
using a scale of 0-3: (0=patient awake; 1=mild, occasionally drowsy but easy to rouse; 2=moderate, frequently drowsy
and easy to rouse and 3=severe, difficult to rouse, unrousable. Numbers of attempts which include total attempts and
good attempts and total drug consumption at the end of
study period (at 24 hrs) were also noted from PCIA pump.
Total attempts are number of clicks on PCIA remote made
by the patient. Good attempts are those clicks in which
patient gets the bolus dose.
Data was entered and analyzed, using SPSS
(Statistical Package for Social Sciences version 13.0).8 Pain
score of the two groups were analyzed by using repeated
measures ANOVA. The P values at specific time points in
nausea vomiting score and sedation score were analyzed by
Mann-Whitney U-test. The overall P value for nausea vomiting score and sedation score were analyzed by proportional odds model for repeated ordinal data. Number of attempts
and total drug consumption were analyzed by student's ttest. P value < 0.05 was considered as significant.

Results

Table 1. Distribution of Median (Interquartile Range) of VAS pain
scores at different time points.
Tramadol

Pethidine

(n=30)

(n=30)

At 1 Hour

6 (4,6)

6 (5,7)

> 0.05

At 6 Hour

5 (4,5)

5 (4,6)

> 0.05

At 12 Hour

4 (4,4)

4 (4,4)

> 0.05

At 24 Hour

2 (1,3)

3 (2,3)

. 0.05

VAS

P-Value

n = Number of patients
VAS = Visual Analogue Scale

Table 2. Percentage of patients with nausea vomiting score and sedation score at different time points.
At 1 Hour
(%)
Nausea
Vomiting Score

At 6 Hour At 12 Hour At 24 Hour
(%)
(%)
(%)

T

P

T

0

73.3

66.7

76.7

1

20.0

26.7

20.0

2

6.7

6.7

3

--

--

P - Value

P

T

P

73.3 80.0

90.0

96.7

93.3

62.7 16.7

6.7

3.3

6.7

3.3

2.3

3.3

3.3

--

--

--

--

--

--

--

--

0.606

P

T

0.829

0.300

0.557

Sedation score
0

83.3

66.7

93.3

76.7 100.0 86.7 100.0 96.7

1

16.7

33.3

6.7

23.3

--

10.0

--

3.3

2

--

--

--

--

--

3.3

--

--

3

--

--

--

--

--

--

--

--

P - Value

0.139

0.073

0.040*

0.317

*P < 0.05
T - Tramadol grouop
P - Pethidine group

Table 3. Comparison of good attempts, total attempts and total drug
consumption at 24 hours.
Tramadol
(n = 30)

Pethidine
(n = 30)

P-Value

Good
attempt

20.70 + 5.76

26.80 + 7.09

< 0.05

Total
attempts

49.06 + 15.23

64.13 + 16.08

< 0.05

Total drug
consumption (mg)

341.66 + 29.19

373.83 + 41.24

< 0.05

There were no significant differences with respect to
age (45.86 ± 3.94 years vs. 46.50 ± 4.42 years) but there was
a significant difference with respect to weight (70.76 ± 5.75
kg vs. 66.49 ± 8.21 kg) in Tramadol group and Pethidine
group respectively.

pain relief at all time points and decrease pain scores progressively (Table 1).

The VAS pain scores between Tramadol and
Pethidine groups were found to be insignificant at different
time. It indicates that both drugs are equivalent in terms of

There was no significant difference in nausea vomiting scores at all time points (Table 2) between the two
groups.
It
was
found
that
at
12
hours

Vol. 56, No. 10, October 2006

*P < 0.05
n = Number of patients
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time point, Tramadol causes significantly less sedation than
Pethidine (P < 0.05) (Table 2).
There was a significant difference (P < 0.05) in the
mean of total number of attempts (20.70 ± 5.76 Vs 26.80 ±
7.19), mean number of good attempts (49.06 ± 15.23 Vs
64.13 ± 16.08) and mean of total drug consumption (341.66
± 29.19 mg Vs 373.83 ± 41.24 mg) in Tramadol group compared to Pethidine group respectively (Table 3).

Discussion
Post-operative pain control is one of the most important aspects of management of surgical patients. Various
studies have been done which show the efficacy of
Morphine and Pethidine in Patient Controlled Intravenous
Analgesia but these drugs are not freely available in our
country. We did this study to identify a drug which is freely
available and comparable to other potent opioids like
Pethidine.
Tramadol is a central-acting analgesic which has
been shown to have dose-related efficacy and is well tolerated.9 It appears to be a valuable addition to the analgesic
armamentarium as a safe and effective agent across a wide
spectrum of acute and chronic painful conditions.9
Most studies indicated the efficacy of Tramadol in
PCIA. Vickers et al10 in their study showed that mean pain
scores for Pethidine was higher than for Tramadol (2.7 vs.
2.6 at rest and 5.2 vs. 4.0 at movement). Silvasti and colleagues11 have found the similar efficacy of Tramadol and
morphine in patient controlled analgesia after microvascular
breast reconstruction. Our study has similar results which
show that Tramadol and Pethidine are equivalent in terms of
pain relief in PCIA.
There was a higher incidence of nausea and vomiting after Tramadol in PCIA. Pang et al12 have shown a higher percentage of nausea and vomiting after Tramadol than
morphine in patient controlled intravenous analgesia. The
observed high incidence of nausea and vomiting might be
dose and rate related with the highest incidence occurring
during the loading phase when a large amount of Tramadol
was given in a short period of time. To mitigate this adverse
effect, a number of preventive measures could be adopted.
Pang and colleagues13 have shown decreased incidence and
severity of nausea and vomiting if metoclopramide was
added to Tramadol PCIA but with an increased incidence of
sedation was noticed with this drug combination. We found
a similar incidence of nausea and vomiting in our study with
no difference between Tramadol and Pethidine in Nausea
and Vomiting Scores.
The dose related incidence of drowsiness and sedation with Pethidine has been reported as between 13 -
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20% compared to Tramadol which is associated with less
sedative effect (10 - 15 %).10 These findings are comparable
to our study in which Tramadol caused less sedation than
Pethidine.
The side effects from most analgesic drugs have a
direct relationship with the dose and the total drug consumption. Various studies have shown less total drug consumption in PCIA Tramadol. Lehman et al14 found that in
patients recovering from general surgery, the mean consumption of Tramadol was 203 mg compared to 175 mg
Pethidine in 18 hours.
The ratio of equipotent doses of two drugs under the
conditions of assessment are termed potency ratio. Vickers
et al10 found the mean consumption of Tramadol and
Pethidine was 642 mg and 606 mg respectively, giving a
potency ratio of Tramadol relative to Pethidine of 0.94. In
our study, the mean drug consumption of Tramadol and
Pethidine was 341 mg and 373 mg respectively. The estimated potency ratio of Tramadol relative to Pethidine in our
study is 1.09 which is slightly higher than proposed by
Vickers.
Since Tramadol has virtually no dependence potential15 and is not a controlled drug in most of the countries in
which it is currently marketed, it is encouraging that
Tramadol is well tolerated and equipotent to Pethidine in
PCIA for management of postoperative pain.
On the basis of the results of our study, we conclude
that the analgesic efficacy of Tramadol and Pethidine in
PCIA after total abdominal hysterectomy is similar. The
incidence of nausea and vomiting is same with both the
drugs but Tramadol causes less sedation than Pethidine.
Tramadol can be used as a suitable alternative to Pethidine
in our setup when the classical opioids are not freely available. The unique composition of Tramadol, with its triple
action accompanied by minimal side-effects, will promote
further research in this area.16
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